News Releases
This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
08 14 2023 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share,...
-
08 02 2023 Ten-fold increase in death risk in individuals with high levels of myeloperoxidase, or MPO, compared to those with low levels, according to analysis of 3,700 patients of MDVIP tested by Quest...
-
07 31 2023 AD-Detect™ Test for Alzheimer's Disease is the first blood-based biomarker test for assessing beta amyloid protein, a recognized marker of Alzheimer's disease, available for consumer purchase to...
-
07 26 2023 Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023Second quarter revenues of $2.34 billion, down 4.7% from 2022 Second quarter reported diluted earnings per share ("EPS") of $2.05, up 4.6% from 2022; and adjusted diluted EPS of $2.30, down 2.5%...
-
07 13 2023 Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer SECAUCUS, N.J. and MELBOURNE, Australia, July 13, 2023 /